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Abstract 
Liver involvement in patients with sickle cell anemia/trait includes a wide range of 
alterations, from mild liver function test abnormalities to cirrhosis and acute liver failure. 
Approximately 15–30% of patients with sickle cell anemia present cirrhosis at autopsy. 
The pathogenesis of cirrhosis is usually related to chronic hepatitis B or C infection or to 
iron overload resulting from the many transfusions received by these patients in their 
lifetime. Thus, cirrhosis has been described almost exclusively in patients with sickle cell 
anemia, while only mild liver abnormalities have been associated with the sickle cell trait. 
In the present case study, we describe a young Mediterranean man carrying a sickle cell 
trait (Hb Sβ+ thalassemia) who developed liver cirrhosis being negative for hepatitis C 
and B viruses or for other causes of cirrhosis and not receiving chronic blood 
transfusions. 
 
 
Sickle cell disease (SCD) is an inherited hematological disorder characterized by the 
presence of the variant hemoglobin Hb S resulting from the substitution of thymine for 
adenine in the β-globin gene, thus encoding the aminoacid valin with glutamic acid in the 
sixth position of the β-chain gene [1]. SCD includes homozygous sickle cell anemia 
requiring life-long blood transfusions, and some heterozygote less severe clinical 
conditions defined as sickle cell trait [2].  
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Patients with sickle cell anemia/trait may suffer from a variety of hepatic alterations. 
The altered shape of red blood cells favors intravascular hemolysis and thus occlusion of 
the liver vascular bed, leading ultimately to tissue injury, which ranges from 
asymptomatic mild liver function test abnormalities to severe acute damage (acute sickle 
hepatic crisis). Furthermore, hemolysis induces deposition of bilirubin causing 
intrahepatic cholestasis and cholelithiasis [3]. Finally, approximately 15–30% of patients 
with sickle cell anemia present cirrhosis at autopsy [4–6]. Rather than a direct 
consequence of the hematological disease itself, the pathogenesis of cirrhosis is widely 
accepted to be related to chronic hepatitis B or C infection and iron overload as a result of 
hemolysis and multiple transfusions that these patients require in their lifetime [3]. Thus, 
it is not surprising that cirrhosis has been described almost exclusively in patients with 
sickle cell anemia, while only mild liver abnormalities have been associated with the sickle 
cell trait [3]. 
We describe the case of a young Mediterranean man carrying a sickle cell trait (Hb Sβ
+ 
thalassemia) who developed liver cirrhosis being negative for hepatitis C (HCV) and 
hepatitis B (HBV) viruses or for other causes of cirrhosis and not receiving chronic blood 
transfusions. 
Case Report 
A 36-year-old Mediterranean man with cryptogenic liver cirrhosis and Hb Sβ
+ thalassemia came to 
our observation to be evaluated for liver transplantation. The diagnosis of sickle cell trait had been made 
in early childhood, while molecular analysis of the β-globin gene in 2001 had shown heterozygosis for 
the Hb S mutation (sequence alteration A>T) and thalassemia β+ (mutation IVS-I.110, sequence 
alteration G>A). Hemoglobin electrophoresis revealed Hb S 71.6%, Hb F 7.40%, Hb A 15.9% and Hb A2 
5.1%. Asymptomatic liver test abnormalities consisting of mild elevation of serum transaminases and 
γ-glutamyltranspeptidase had been detected for the first time at the age of 30 years. A few years later, in 
2003, due to a progressive worsening of liver function tests and the appearance of hepatomegaly and 
scleral jaundice, the patient had undergone an extensive work-up, including liver biopsy, to determine 
the cause and stage of liver disease. 
Biochemistry assessment showed elevation of serum transaminases (aspartate aminotransferase: 
113 U/l; alanine aminotransferase: 35 U/l) and cholestatic enzymes (γ-glutamyltranspeptidase: 206 U/l; 
alkaline phosphatase: 251 U/l), hyperbilirubinemia (total: 4.61 mg/dl; conjugated bilirubin: 2.41 mg/dl), 
and hypergammaglobulinemia. White blood count, platelets, coagulative tests, albumin, renal function, 
electrolytes and metabolic parameters were normal, serum ferritin was markedly elevated (1,249 ng/ml), 
but the genetic analyses for hereditary hemochromatosis did not unveil mutations for the HFE, 
transferrin receptor 2 and ferroportin genes. Hepatotropic viruses (HCV and HBV, cytomegalovirus, 
Epstein-Barr virus) tested negative. Anti-nuclear, anti-mitochondria, anti-LKM antibodies, and anti-
neutrophil cytoplasmic antibodies were absent, while a low-titer aspecific positivity for the anti-smooth 
muscle antibody was found. Serum ceruloplasmin and α-1-antripsin levels were within the normal 
range. The patient was abstinent for alcohol and his body mass index was normal. Liver histology 
documented cirrhosis with large fibrotic septa and regenerative nodules; sinusoids appeared dilated and 
engorged by red blood cells with an altered morphology; finally, Pearl staining revealed iron deposition 
in Kupffer cells and hepatocytes (second-degree siderosis). Liver ultrasound showed hepatomegaly with 
a nodular coarse and gallbladder stones. It is important to note that until 2003, when cirrhosis was 
diagnosed, the hemoglobin serum levels had remained stable approximately around 8 g/dl and the 
patient had received a low number of blood transfusions in his entire life (<10 units of red packed blood 
cells). 
The patient then started iron chelating therapy with desferrioxamine which was stopped two years 
later because of a significant reduction in serum ferritin (419 ng/ml); at that time the hepatic iron 
concentration was 223 μg Fe/g liver (normal value <400 μg Fe/g liver) at the Super Quantum 
Interference Device (SQUID 5700 3-Channel, Tristan technologies Inc, San Diego, USA). Despite this, 
liver function tests progressively deteriorated and the patient was referred to our hospital at the end of 
2006 to be evaluated for liver transplantation. At that time, laboratory test showed marked 
hyperbilirubinemia (total: 13.02 mg/dl; conjugated bilirubin: 7.31 mg/dl) and development of  
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coagulopathy (INR: 1.54) and hypoalbuminemia (2.95 g/dl). Serum ferritin was close to the upper 
normal limit (316 ng/ml). The patient was in class B9 of Child-Pugh (mild ascites and encephalopathy), 
while MELD score was 21. Upper endoscopy showed medium-sized esophageal varices and portal 
hypertensive gastropathy. No cardiac, renal or respiratory diseases were found and the patient was 
accepted in the waiting list for liver transplantation. 
Subsequently, his clinical conditions progressively deteriorated with a sudden exacerbation of the 
hematological disease. Indeed, the patient presented chronic hemolysis requiring blood transfusions 
every 2–3 weeks to maintain a hemoglobin level higher than 8 g/dl, while serum ferritin increased up to 
8,891 ng/ml and iron-chelating therapy was restarted in June 2008. Unfortunately, the patient died in 
August 2008 from septic shock before being transplanted. 
Discussion 
Autopsy series indicate a 16–29% prevalence of cirrhosis in sickle cell anemia patients 
[4–6]. In almost all cases, cirrhosis develops in the presence of homozygous sickle cell 
anemia as a consequence of chronic hepatitis B or C infection or iron overload due to the 
multiple blood transfusions that these patients require in their lifetime [3]. In contrast, 
patients with microdrepanocytosis rarely show hepatic involvement, the severity of which 
appears to be mild, particularly in the white Mediterranean population [7]. An Italian 
study in patients with sickle cell anemia, sickle cell trait, and sickle β thalassemia 
documented that only 2 of 142 patients had significantly abnormal liver function tests, 
with marginal abnormalities being seen in the remainder [8]; moreover, both patients 
were positive for HBsAg and HCV antibody, so that their liver disease could be related to 
the viral infection rather than to the hematological disorder [8]. 
The major finding in our case is represented by the possibility that a patient carrying a 
sickle cell trait (Hb Sβ
+ thalassemia) and not receiving chronic blood transfusions can 
develop liver cirrhosis being negative for HCV and HBV or for other causes of cirrhosis. 
Up to now, only very rare cases of unexplained cirrhosis have been diagnosed in patients 
with microdrepanocytosis. Namely, Lerut et al. [9] reported a case of a Sicilian woman 
with Sβ
+ thalassemia with cryptogenic cirrhosis who developed allograft dysfunction due 
to intrahepatic sickling after liver transplantation; however, the positivity for anti-nuclear 
antibodies (1/160) may suggest the presence of a concomitant autoimmune hepatitis as a 
possible cause of cryptogenic cirrhosis. A second case of cryptogenic cirrhosis has been 
recently described in a Ghanaian man with Sβ
+ thalassemia [10, 11]. Interestingly, as in 
our case, this patient was asymptomatic for liver disease until adulthood, when he 
presented features of subacute liver failure and histological cirrhosis with superimposed 
cholestasis and necrosis. 
It remains unclear why a patient with an apparently benign genotype of SCD can 
develop cirrhosis in absence of any other etiological cause. Our patient experienced the 
typical manifestations of liver failure and portal hypertension, although jaundice and 
mixed hyperbilirubinemia represented a prominent feature even when cirrhosis was 
well-compensated. Moreover, the liver biopsy, beside the histological cirrhosis, showed a 
second degree of siderosis and evidence of sickling in the liver sinusoids. Unfortunately, 
the amount of hepatic iron was not quantified before iron depletion therapy. Thus, it can 
be hypothesized that multiple concomitant pathophysiological events, represented by 
cholestasis, sickling-related ischemia, and liver iron deposition, may have contributed to 
the development of chronic liver disease and, ultimately, cirrhosis. With regard to iron 
deposition, although the major mutations related to genetic hemochromatosis have been 
searched and ruled out, we cannot exclude with certainty the presence of other rare gene 
defects of iron metabolism [12].  
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An intriguing observation emerging from our case study is related to the onset of the 
clinical manifestations and complications of cirrhosis temporally related to a sudden 
deterioration of the hematological disease. In fact, contrary to what occurred prior to 
2007, when the hemoglobin levels remained quite stable, the patient presented chronic 
hemolysis requiring blood transfusions every 2–3 weeks and iron-chelating therapy in the 
last year. 
In conclusion, this case report documents the possibility that patients with sickle cell 
trait (Hb Sβ
+ thalassemia) can develop cirrhosis even in the absence of other manifest 
causes of chronic liver disease. This observation also suggests that patients with 
heterozygote conditions should be followed to exclude significant hepatic involvement. 
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